neuroscience

News

Mobile ADHD awareness game launches in Germany

Attention-deficit hyperactivity disorder (ADHD) in adults is not well understood and highly underdiagnosed, but the developers of a mobile game designed to raise awareness

News

BMS wagers $14bn on Karuna’s schizophrenia drug

Bristol-Myers Squibb has decided to gamble on the FDA approving Karuna Therapeutics’ schizophrenia drug candidate KarXT next year, agreeing to buy the company for approxim

News

AbbVie swoops on Pfizer spin-out Cerevel with $8.7bn offer

AbbVie has announced its second major takeover deal in the space of a few days, offering $8.7 billion to buy central nervous system drug specialist Cerevel Therapeutics, w

R&D

How to advance more late-stage neuroscience drugs to regulat...

As a practicing neuropsychiatrist for more than a decade, I witnessed firsthand the profound unmet need in neurological and psychiatric disorders including epilepsy, neurodegenerative disea

News

Roche sticks with molecular glue, partnering Monte Rosa

Roche seems determined to develop a commanding position in the emerging molecular glue category, signing up to a $2 billion partnership with Monte Rosa Therapeutics that i

News

MSD gives warning to UK ahead of $1.3bn facility work

In 2017, MSD made the decision to open a $1.32 billion, 220,000 sq ft research facility in the heart of London’s ‘knowledge quarter’ around King’s Cross.

Mobile ADHD awareness game launches in Germany

BMS wagers $14bn on Karuna’s schizophrenia drug

AbbVie swoops on Pfizer spin-out Cerevel with $8.7bn offer

How to advance more late-stage neuroscience drugs to regulat...

Roche sticks with molecular glue, partnering Monte Rosa

MSD gives warning to UK ahead of $1.3bn facility work

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

neuroscience

Editor's Picks